INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Bio Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the closing of its underwritten public offering of 3,980,768
View HTML
Toggle Summary Atara Bio Announces Pricing of Its $180.0 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of 3,461,538
View HTML
Toggle Summary Atara Bio Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of
View HTML
Toggle Summary Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center
Activated T-Cell Technology Designed to Harness Immune System to Fight Cancer and Infectious Disease
View HTML
Toggle Summary Atara Biotherapeutics, Inc. to Present at Upcoming Investor Conferences in June 2015
SOUTH SAN FRANCISCO, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that it will webcast its presentations at the below listed investor conferences in June 2015. Isaac Ciechanover, the company's President and Chief Executive Officer, will present
View HTML
Toggle Summary Update: Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV+ Lymphoma after Hematopoietic and Solid Organ Allografts at the 2015 American Society of Clinical Oncology Annual Meeting
View HTML
Toggle Summary Atara Biotherapeutics' Collaborating Investigators to Present Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV+ Lymphoma After Hematopoietic and Solid Organ Allografts at the 2015 American Society of Clinical Oncology Annual Meeting
View HTML
Toggle Summary Atara Biotherapeutics, Inc. to Present at the UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, the company's President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 4:00 pm EDT in New
View HTML
Toggle Summary Atara Biotherapeutics Announces First Quarter 2015 Results
SOUTH SAN FRANCISCO, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the first quarter ended March 31, 2015.
View HTML
Toggle Summary EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015
SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic T lymphocytes activated against Epstein-Barr
View HTML